Snowden Capital Advisors LLC Genmab A/S Transaction History

Snowden Capital Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.43 - $32.77 $181,336 - $224,834	6,861 New	6,861 $205,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $5,466 - $6,547	155 Added 2.78%	5,721 $201,000
Q2 2023 Aug 14, 2023	BUY	$37.4 - $42.94 $5,909 - $6,784	158 Added 2.92%	5,566 $211,000
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $22,079 - $27,358	633 Added 13.26%	5,408 $204,000
Q4 2022 Feb 13, 2023	BUY	$33.8 - $47.06 $161,395 - $224,711	4,775 New	4,775 $202,000
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $13,091 - $16,784	-423 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.87 - $47.12 $15,173 - $19,931	423 New	423 $16,000
Q1 2020 Jan 08, 2024	SELL	$17.15 - $25.22 $1.78 Million - $2.62 Million	-103,900 Closed	0 $0
Q4 2019 Jan 08, 2024	BUY	$18.88 - $24.14 $98,176 - $125,528	5,200 Added 5.27%	103,900 $23.2 Million
Q3 2019 Jan 08, 2024	BUY	$18.0 - $21.38 $1.67 Million - $1.99 Million	92,979 Added 1625.22%	98,700 $20 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Snowden Capital Advisors LLC with notifications on news.